Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 984

1.

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2005 Aug;21(8):1317-27.

PMID:
16083542
2.

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2006 Jan;22(1):49-59. Erratum in: Curr Med Res Opin. 2006 Aug;22(8):1451.

PMID:
16393430
3.

Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.

Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R.

Curr Med Res Opin. 2006 Mar;22(3):483-94.

PMID:
16574032
4.

Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.

Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R.

Pharmacogenet Genomics. 2006 Nov;16(11):771-4.

PMID:
17047484
5.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

6.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.

Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B.

Curr Med Res Opin. 2002;18(3):129-38.

PMID:
12094822
7.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
8.

Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.

Boada-Rovira M, Brodaty H, Cras P, Baloyannis S, Emre M, Zhang R, Bahra R; 322 Study Group.

Drugs Aging. 2004;21(1):43-53.

PMID:
14715043
9.

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group.

Neurology. 2001 Aug 28;57(4):613-20. Erratum in: Neurology 2001 Dec 11;57(11):2153.

PMID:
11524468
10.

Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.

Chiu PY, Dai DE, Hsu HP, Lee C, Lin JJ, Kuo HC, Huang YC, Liu YC, Tsai CP.

Clin Drug Investig. 2009;29(11):729-38. doi: 10.2165/11315320-000000000-00000.

PMID:
19813776
11.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
12.

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group.

Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69.

PMID:
15920715
13.

Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.

Johannsen P, Salmon E, Hampel H, Xu Y, Richardson S, Qvitzau S, Schindler R; AWARE Study Group.

CNS Drugs. 2006;20(4):311-25. Erratum in: CNS Drugs. 2006;20(10):866.

PMID:
16599649
14.

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.

Farlow MR, Alva G, Meng X, Olin JT.

Curr Med Res Opin. 2010 Feb;26(2):263-9. doi: 10.1185/03007990903434914.

PMID:
19929593
15.

A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.

Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS.

Int J Clin Pract. 2002 Jul-Aug;56(6):441-6.

PMID:
12166542
16.

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.

Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, Zhang R, Bahra R.

Int J Geriatr Psychiatry. 2004 Jan;19(1):58-67.

PMID:
14716700
17.

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group.

Curr Med Res Opin. 2002;18(6):347-54.

PMID:
12442882
18.

An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.

Aguglia E, Onor ML, Saina M, Maso E.

Curr Med Res Opin. 2004 Nov;20(11):1747-52.

PMID:
15537474
19.
20.

Supplemental Content

Support Center